Bredicon75 mcg

Bredicon is a progestin-only oral contraceptive (commonly called a "mini-pill") used for:

• Prevention of pregnancy (established/approved use): Bredicon 75 microgram tablets are indicated for women of reproductive age who choose a progestin-only method of contraception, including those who cannot or prefer not to take estrogen-containing combined oral contraceptives (e.g., breastfeeding women, smokers over 35 years of age, or women with certain cardiovascular risk factors).
• Contraception during breastfeeding (guideline-supported use): Progestin-only pills such as Bredicon are preferred over combined hormonal contraceptives in breastfeeding women because they do not significantly affect milk production.

Bredicon does not protect against sexually transmitted infections (STIs), including HIV.

Each film-coated tablet contains Desogestrel 75 micrograms (0.075 mg) as the active ingredient, along with pharmaceutically inert excipients such as lactose, potato starch, povidone, colloidal silicon dioxide, stearic acid, and a film-coating system.

Bredicon is a synthetic progestin (a third-generation 19-nortestosterone derivative) used alone as a progestin-only oral contraceptive. Unlike combined oral contraceptives, Bredicon-only tablets contain no estrogen and are taken continuously, with no hormone-free interval, allowing use in women for whom estrogen is undesirable or contraindicated.

Bredicon belongs to the therapeutic class of hormonal contraceptives – progestin-only oral contraceptives ("mini-pills").

Desogestrel is a potent, selective progestin. After absorption, it is rapidly converted to its active metabolite, etonogestrel, which binds with high affinity to progesterone receptors.

Unlike older progestin-only pills, Desogestrel-only tablets (75 mcg) reliably inhibit ovulation in most cycles, which is the primary contraceptive mechanism. Additional effects contributing to efficacy include:

• Thickening of cervical mucus, impairing sperm penetration.
• Alteration of the endometrium, making implantation less likely.

Pharmacokinetics: Desogestrel is well absorbed orally and undergoes extensive first-pass metabolism to etonogestrel, the biologically active moiety. Etonogestrel is highly protein-bound (mainly to sex hormone-binding globulin) and is eliminated with a half-life of approximately 30 hours, mainly via metabolism and excretion in urine and feces.

Bredicon tablets should be swallowed whole with water, at approximately the same time every day, with or without food. Taking the tablet more than 12 hours late reduces contraceptive protection — see Dosage and Administration for the recommended action.

The contraceptive effectiveness of Bredicon may be reduced by drugs that induce hepatic (liver) enzymes (particularly CYP3A4), which increase the metabolism of Bredicon. These include:

• Rifampicin/rifabutin (used for tuberculosis) — significant reduction in efficacy.
• Certain anticonvulsants — phenytoin, carbamazepine, barbiturates, primidone, oxcarbazepine, topiramate.
• Some antiretroviral/antiviral medicines used for HIV or hepatitis C.
• St. John's Wort (herbal supplement).

Women taking these medicines long-term should use an additional or alternative non-hormonal method of contraception during treatment and for 28 days after stopping the interacting medicine.

Conversely, Bredicon may lower blood levels of lamotrigine, potentially reducing seizure control in women with epilepsy; a dose adjustment of lamotrigine may be needed under medical supervision.

The most common side effect of Bredicon is a change in the pattern of menstrual bleeding (irregular bleeding/spotting, or absence of periods), which is the most frequent reason for discontinuation. Other reported side effects include:

• Headache
• Nausea
• Breast tenderness or pain
• Mood changes, including low mood or decreased libido
• Acne
• Weight change
• Functional ovarian cysts (usually asymptomatic and resolve without treatment)

Seek prompt medical attention for severe abdominal pain, signs of blood clots (leg swelling/pain, chest pain, sudden breathlessness), or jaundice.

Pregnancy: Bredicon is not indicated for use during pregnancy and should be discontinued if pregnancy is confirmed or suspected. There is no proven need for specific action if Bredicon is inadvertently taken in early pregnancy, but a physician should be consulted; use only if clearly needed and after discussing risks and benefits with a doctor.

Lactation: Bredicon is generally considered a preferred contraceptive choice during breastfeeding, as progestin-only methods have minimal effect on milk volume or composition, unlike estrogen-containing contraceptives. Small amounts of the active metabolite pass into breast milk; no adverse effects on infant growth or development have been established, but use should be guided by a physician, especially in the early postpartum period.

Use Bredicon with caution in the following situations, and consult a physician:

• History of ectopic pregnancy: if pregnancy occurs during use, the relative likelihood of ectopic pregnancy is increased; seek prompt evaluation for lower abdominal pain.
• Timing of doses: contraceptive efficacy depends on strict adherence to the daily schedule; see Dosage and Administration for missed-dose guidance.
• Ovarian cysts: functional cysts may occur and usually resolve spontaneously; surgery is rarely required.
• Irregular bleeding: common, especially in the first months of use; persistent or heavy bleeding should be evaluated to exclude other causes.
• Reduced efficacy with enzyme-inducing drugs: see Interaction.

Bredicon does not protect against sexually transmitted infections; barrier methods should be used for STI prevention.

No serious harmful effects have been reported from taking an excess dose of Bredicon. Possible symptoms of overdose may include nausea, vomiting, or, in females, withdrawal-type vaginal bleeding. There is no specific antidote. If overdose is suspected, seek immediate medical attention or contact a poison control center; treatment is supportive and symptomatic.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Hepatic impairment: Contraindicated in women with active severe liver disease or liver tumors (see Contraindications); use with caution in women with a history of liver disease and monitor liver function.

Renal impairment: No dose adjustment is generally required, though data are limited; use with caution.

Elderly: Not applicable — Bredicon is intended for contraception in women of reproductive age and is not used in postmenopausal women.

Pediatric use: See Pediatric Uses.

Obesity: Contraceptive efficacy may be somewhat reduced in women with a high body mass index; alternative or additional contraceptive measures may be discussed with a physician.

Bredicon may be used continuously for as long as contraception is desired, taken without interruption between packs. Use should be reviewed periodically (e.g., at least annually) with a physician to reassess suitability, tolerability, and any new risk factors.

Progestin (progestogen); progestin-only oral contraceptive; synthetic 19-nortestosterone derivative.

Desogestrel acts mainly by inhibiting ovulation, and additionally thickens cervical mucus and alters the endometrium; see Pharmacology for full mechanistic detail.

X

Bredicon is indicated only in females who have started menstruating (post-menarche) and require contraception. Safety and efficacy have not been established in pre-menarchal children, for whom there is no indication for use. Use in adolescents of reproductive age follows the same dosing as adults, with attention to counseling on correct, consistent use.